Searching across hundreds of databases
Acute promyelocytic leukemia (APL) is driven by the oncoprotein PML-RARα, which antagonizes myeloid differentiation and promotes APL-initiating cell self-renewal. Combined all-trans retinoic acid (ATRA) with arsenic trioxide (As2O3) or chemotherapy dramatically improves the prognosis of APL patients. Here we report that expression of pseudokinase Tribble 3 (TRIB3) associates positively with APL progression and therapeutic resistance. The elevated TRIB3 expression promotes APL by interacting with PML-RARα and suppressing its sumoylation, ubiquitylation, and degradation. This represses PML nuclear body assembly, p53-mediated senescence, and cell differentiation, and supports cellular self-renewal. Genetically inhibiting TRIB3 expression or combination of a peptide disturbing TRIB3/PML-RARα interaction with ATRA/As2O3 eradicates APL by accelerating PML-RARα degradation. Our study provides insight into APL pathogenesis and a potential therapeutic option against APL.
Pubmed ID: 28486108 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
Statistical analysis software that combines scientific graphing, comprehensive curve fitting (nonlinear regression), understandable statistics, and data organization. Designed for biological research applications in pharmacology, physiology, and other biological fields for data analysis, hypothesis testing, and modeling.
View all literature mentionsThis monoclonal targets CD11b
View all literature mentionsThis monoclonal targets Ly-6G/Ly-6C
View all literature mentionsThis monoclonal targets CD11b
View all literature mentionsThis monoclonal targets His Tag
View all literature mentionsThis polyclonal targets His-tag
View all literature mentionsThis monoclonal targets anti-HA-tag
View all literature mentionsThis polyclonal targets HA-Tag-Agarose
View all literature mentionsThis polyclonal targets HA Tag
View all literature mentionsThis monoclonal targets Myc Tag
View all literature mentionsThis unknown targets Myc Tag
View all literature mentionsThis monoclonal targets Green Fluorescent Protein
View all literature mentionsThis monoclonal targets anti-DDDDK-tag
View all literature mentionsThis polyclonal targets DDDDK-Tag (Enterokinase Cleavage Site) Agarose Conjugate
View all literature mentionsThis polyclonal targets DDDDK-Tag (ECS/Enterokinase Cleavage Site)
View all literature mentionsThis monoclonal targets RARA (C-term)
View all literature mentionsThis polyclonal targets PSME3
View all literature mentionsThis polyclonal targets PSME1
View all literature mentionsThis monoclonal targets RNF4 (C-term)
View all literature mentionsThis monoclonal targets ACTB
View all literature mentionsThis monoclonal targets PIAS1
View all literature mentionsThis polyclonal targets PIAS1
View all literature mentionsThis polyclonal targets Sumo3
View all literature mentionsThis polyclonal targets Human SUMO2 (C-term)
View all literature mentionsThis monoclonal targets SUMO1
View all literature mentionsThis monoclonal targets P16 antibody produced in mouse
View all literature mentionsThis monoclonal targets Rb1
View all literature mentionsThis monoclonal targets p21 Waf1/Cip1
View all literature mentionsThis monoclonal targets p53 (1C12) Mouse mAb
View all literature mentionsThis polyclonal targets Phospho-p53 (Ser15)
View all literature mentionsThis polyclonal targets Human PML
View all literature mentionsThis monoclonal targets PML Protein antibody [C7]
View all literature mentionsThis polyclonal targets PML+RARA Fusion antibody
View all literature mentionsThis monoclonal targets Human TRIB3
View all literature mentionsMus musculus with name C57BL/6-Pmltm1(PML/RARA)Ley/J from IMSR.
View all literature mentionsThe SciCrunch Infrastructure was developed as a cooperative data platform to be used by diverse communities in making data more FAIR.
scicrunch.org
